Different studies have demonstrated that IPMN is a major risk factor for PDAC (having PDAC 1% annual prevalence of concomitance with IPMN) [79–82], but some patients with IPMN have even higher risk of developing PDAC, in particular patients > 70 years and women [79, 82], patients with benign gastric-type IPMN without guanine nucleotide-binding protein alpha-stimulating (GNAS) mutations [82–84] and patients with IPMN and family history of PDAC especially with affected first-degree relatives [82, 85, 86]. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.